Outpatient treatment of Covid-19 with metformin, ivermectin, and fluvoxamine and the development of Long Covid over 10-month follow-up

BACKGROUND: Long Covid is an emerging chronic illness potentially affecting millions, sometimes preventing the ability to work or participate in normal daily activities. COVID-OUT was an investigator-initiated, multi-site, phase 3, randomized, quadruple-blinded placebo-controlled clinical trial (NCT...

Descripción completa

Detalles Bibliográficos
Autores principales: Bramante, Carolyn T., Buse, John B., Liebovitz, David, Nicklas, Jacinda, Puskarich, Michael A., Cohen, Ken, Belani, Hrishikesh, Anderson, Blake, Huling, Jared D., Tignanelli, Christopher, Thompson, Jennifer, Pullen, Matthew, Siegel, Lianne, Proper, Jennifer, Odde, David J., Klatt, Nichole, Sherwood, Nancy, Lindberg, Sarah, Wirtz, Esteban Lemus, Karger, Amy, Beckman, Kenny, Erickson, Spencer, Fenno, Sarah, Hartman, Katrina, Rose, Michael, Patel, Barkha, Griffiths, Gwendolyn, Bhat, Neeta, Murray, Thomas A., Boulware, David R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9810227/
https://www.ncbi.nlm.nih.gov/pubmed/36597543
http://dx.doi.org/10.1101/2022.12.21.22283753

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9810227/
https://www.ncbi.nlm.nih.gov/pubmed/36597543
http://dx.doi.org/10.1101/2022.12.21.22283753

Ejemplares similares